A Phase I Study of Oral MEK162 in Japanese Patients With Advanced Solid Tumors

Summary

In this study, MEK162 will be administered to Japanese patients with advanced solid tumors whose disease has progressed despite standard therapy or for whom no standard therapy exists. The trial will investigate the safety and tolerability and determine the MTD of MEK162 in Japanese patients.

Timeline

Start

2011-11

Primary completion

2014-04

Completion

2018-02-01

Drugs

Indications